Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Prediction of response to interferon therapy in multiple sclerosis.
Intermittent Atrioventricular Block following Fingolimod Initiation.
Disease Suppression Persists With Ozanimod at 72 Weeks in MS
The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients.
Ozone: a multifaceted molecule with unexpected therapeutic activity.
HLA-B7-Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis.
Is multiple sclerosis an autoimmune disease?
Dynamics of saccade parameters in multiple sclerosis patients with fatigue.
Regulation of encephalitogenicity of neuroantigen-primed T cells by nitric oxide: Implications for multiple sclerosis.
Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
New Disease-Modifying Therapies and New Challenges for MS.
Multiple sclerosis relapses and depression.
A CB(1)/CB(2) receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin.
Associations of alcohol consumption with clinical and MRI measures in multiple sclerosis.
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Suppression of Brain Mast Cells Degranulation Inhibits Microglial Activation and Central Nervous System Inflammation.
Combined EPR and Molecular Modeling Study of PPI Dendrimers Interacting with Copper Ions: Effect of Generation and Maltose Decoration.
A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10.
Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.
"Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis.
Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs.
Psychiatric symptoms in patients with multiple sclerosis.
Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis.
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.

Pages